Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Provides 2023 Pipeline Update

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
February 23, 2023 16:16 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
February 21, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
January 19, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
January 16, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Rhinitis Pipeline Appears Robust With 32+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

New York, USA, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Rhinitis Pipeline Appears Robust With 32+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight The prevalence of...
January 05, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 17, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 14, 2022 18:20 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 07, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 02, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients

FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...